Evolent Health Company Profile (NYSE:EVH)

Evolent Health trades on the New York Stock Exchange (NYSE) under the ticker symbol "EVH."

Evolent Health Inc (NYSE:EVH) issued its quarterly earnings results on Tuesday, May, 9th. The company reported ($0.26) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.15) by $0.11. The company had revenue of $106.80 million for the quarter, compared to analysts' expectations of $104.38 million. Evolent Health had a negative return on equity of 5.54% and a negative net margin of 69.04%. Evolent Health's revenue for the quarter was up 116.2% compared to the same quarter last year. During the same quarter last year, the company earned ($0.16) EPS. View Evolent Health's Earnings History.

11 brokers have issued 12-month price objectives for Evolent Health's shares. Their predictions range from $24.00 to $31.00. On average, they expect Evolent Health's stock price to reach $27.88 in the next twelve months. View Analyst Ratings for Evolent Health.

Here are some recent quotes from research analysts about Evolent Health stock:

• 1. According to Zacks Investment Research, "Evolent Health, Inc. is involved in the healthcare delivery and payment markets. The company provides technology-enabled services platform for providers to transition their organization in value-based payment models. Evolent Health, Inc. is based in Arlington, Virginia. " (5/4/2017)
• 2. Cantor Fitzgerald analysts commented, "4Q16 results were solid. Adjusted 4Q16 revenue of $90 million (+92.6% y/y) was above consensus expectations of $85.3 million. Revenue included contributions from Valence and Aldera. Revenue growth was driven by contributions from Valence and Aldera and by an increase in the number of lives on the company’s platform. The number of lives grew 181.5% y/y, reaching about 2.0 million lives in 4Q16. EVH also added another 600,000 lives to the platform in January 2017. Adjusted transformation revenue of $12.1 million increased 12% y/y. Transformation revenue can fluctuate quarter-to-quarter due to the timing of customer contracts and the scope of delivery. Adjusted platform and operation revenue of $77.9 million (+116.8%) benefited from an increased number of lives on the platform. Average PMPM was $12.87 in 4Q16 vs. $16.70." (3/1/2017)

Some companies that are related to Evolent Health include Healthequity (HQY), WebMD Health Corp. (WBMD), Inovalon Holdings (INOV), Premier (PINC), Teladoc (TDOC), Omnicell (OMCL), Quality Systems (QSII), HealthStream (HSTM), Merge Healthcare (MRGE), Computer Programs & Systems (CPSI), Streamline Health Solutions (STRM), Medical Transcription Billing Corp (MTBC), Everyday Health (EVDY), Imprivata (IMPR) and MedAssets (MDAS).

(EVH) raised $150 million in an IPO on Friday, June 5th 2015. The company issued 10,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan and Goldman Sachs served as the underwriters for the IPO and Wells Fargo Securities, William Blair, SunTrust Robinson Humphrey and Leerink Partners were co-managers.

Evolent Health's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include JPMorgan Chase & Co. (9.62%), FMR LLC (8.61%), Pennant Capital Management LLC (5.41%), Vanguard Group Inc. (4.81%), TPG Group Holdings SBS Advisors Inc. (2.50%) and TimesSquare Capital Management LLC (2.49%). Company insiders that own Evolent Health stock include Board Co Advisory, Chad Pomeroy, Cheryl Scott, Frank J Williams, Gary Piefer, Jonathan Weinberg, Michael D'amato, Nicholas Mcgrane, Seth Blackley, Steve Wigginton, Thomas Peterson III, Tpg Growth Ii Advisors, Inc and Upmc. View Institutional Ownership Trends for Evolent Health.

Evolent Health's stock was sold by a variety of institutional investors in the last quarter, including Granahan Investment Management Inc. MA, TPG Group Holdings SBS Advisors Inc., Peregrine Capital Management LLC, Credit Suisse AG, Gilder Gagnon Howe & Co. LLC, TimesSquare Capital Management LLC, Morgan Stanley and Bank of New York Mellon Corp. Company insiders that have sold Evolent Health stock in the last year include Board Co Advisory, Chad Pomeroy, Cheryl Scott, Frank J Williams, Jonathan Weinberg, Nicholas Mcgrane, Seth Blackley, Steve Wigginton, Thomas Peterson III, Tpg Growth Ii Advisors, Inc and Upmc. View Insider Buying and Selling for Evolent Health.

Evolent Health's stock was acquired by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., FMR LLC, MARSHALL WACE ASIA Ltd, Marshall Wace North America L.P., Mackenzie Financial Corp, UBS Asset Management Americas Inc., Vanguard Group Inc. and Edmond DE Rothschild Holding S.A.. Company insiders that have bought Evolent Health stock in the last two years include Gary Piefer and Michael D'amato. View Insider Buying and Selling for Evolent Health.

Shares of Evolent Health can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Evolent Health stock can currently be purchased for approximately $23.50.